AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05529537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: excersize
Description: upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
Study NCT05529537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: excersize
Description: upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
Study NCT06122389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554; Chidamide analog tablets
Description: SHR2554 + Chidamide analog tablets
Study NCT06122389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 analog tablets; Chidamide
Description: SHR2554 analog tablets + Chidamide
Study NCT06723171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06715878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zero Ischemia Robot-Assisted Laparoscopic Microwave Ablation Assisted suture-less Enucleation
Description: Under the visualization of ultrasound contrast imaging through the operative channel, a microwave ablation probe was inserted into the tumor (at the interface between the tumor and kidney, close to the tumor base). The microwave ablation device was used, with a power setting of 70 W for initiating microwave ablation. Depending on the tumor volume and depth, 1-3 ablation cycles were performed, with each cycle lasting 1-3 minutes. After reaching the pseudocapsule of the tumor, a combination of blunt dissection, sharp cutting, and blunt dissection was employed to separate the tumor from the renal parenchyma . The renal artery was not occluded during the procedure.If intraoperative injury to the collecting system is suspected, the collecting system should be sutured normally, while simultaneously suturing the outer layer of renal parenchyma to prevent urine leakage.
Study NCT06715878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted laparoscopic partial nephrectomy
Description: robotic-assisted laparoscopic partial nephrectomy
Study NCT05036941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acteev™ Masks
Description: Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 1 will be supplied adequate number of Acteev™ N95 masks YQD8008 during 8-hour shift and Acteev™ fabric masks for community use.
Study NCT05036941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Masks
Description: Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 2 will be supplied with adequate number of standard N95 masks during 8-hour shift and fabric mask for community use.
Study NCT04776408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung recruitment combined inhaled Nitric oxide
Description: Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
Study NCT04776408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung recruitment
Description: Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
Study NCT06717971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame-based multicomponent training program.
Description: The training program for the intervention group utilized the Nintendo Switch game WarioWare: Move It,. Participants engaged with the game through Joy-Con controllers, completing rapid micro-games designed to meet specific movement-oriented objectives. Each game session lasted approximately five seconds, requiring participants to quickly adapt to various physical actions and postures, such as waving, jumping, swinging arms, rotating, and mimicking object movements. The game's dynamic structure provides an engaging experience that promotes physical coordination, reaction speed, upper and lower limb strength, and hand-eye coordination through diverse movement patterns. Switching between tasks compels players to adjust to varying motion demands swiftly, enhancing physical agility while strengthening attention-shifting and quick decision-making skills.
Study NCT06717971 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: The standard care program for the control group is grounded in routine practices of long-term care facilities, aiming to sustain and enhance the physical and mental well-being of elderly residents through structured group activities. These activities encompass tailored fitness exercises, horticultural therapy, and sedentary group engagements for older adults. The fitness exercises are adapted to meet the varying physical conditions of participants, ensuring a safe and comfortable environment that promotes moderate physical activity. Horticultural therapy involves hands-on planting and tending to plants, stimulating the senses, and fostering emotional regulation, contributing to improved psychological health. Sedentary activities, such as tabletop games, emphasize social interaction and cognitive maintenance by promoting a relaxed social environment that helps participants remain cognitively engaged.
Study NCT06729879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga eye exercises group:
Description: Yoga eye exercises
Study NCT06729879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release-postural correction exercises group
Description: Myofascial release-postural correction exercises
Study NCT06729879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yoga eye exercises, myofascial release-postural correction exercises group
Description: Yoga eye exercises, myofascial release-postural correction exercises group
Study NCT06729879 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: no intervention
Study NCT06727643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: trunk muscle strength
Description: force that represents the endurance of the body.
Study NCT06727643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk muscle strength
Description: force that represents the endurance of the body.
Study NCT06727643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Core Strength
Description: back and abdominal muscle endurance
Study NCT06727643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Strength
Description: back and abdominal muscle endurance
Study NCT06727643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Balance
Description: steady state
Study NCT06727643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance
Description: steady state
Study NCT06729593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
Study NCT06729593 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Study NCT06729593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Study NCT06729593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Study NCT06728605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Description: Patients randomly assigned to EECP received 3 1/2-h sessions of EECP for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 300 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
Study NCT06728605 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Patients randomly assigned to sham group received 3 1/2-h sessions of sham treatment for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 70 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
Study NCT06728592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Magnetic Resonance Imaging
Description: 0.23T Low-field Magnetic Resonance Imaging
Study NCT06728046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESPB
Description: Participants will receive ultrasound-guided ESPB preoperatively, using 40 ml of 0.3% ropivacaine.
Study NCT06728046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Participants will receive postoperative PCA with a formulation of 200 µg sufentanil diluted to 100 ml. The PCA settings will include a background dose of 3 ml/hour, a lockout time of 15 minutes, and a bolus dose of 2 ml.
Study NCT06728306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality-Based Relaxation
Description: Participants experienced a 20-minute immersive relaxation session using the virtual reality headset and the Nature Treks application, while seated comfortably. Participants were instructed to select the natural environment they found most relaxing from options such as Blue Ocean, Orange Sunset, Violet Down, White Winter, and Green Meadows, and spent 20 minutes immersed in their chosen virtual environment.
Study NCT06728306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-immersive VR-Based Exergaming
Description: Participants engaged in a 20-minute calisthenic exercise session guided by the Kinect Adventures game on the Xbox Kinect 360 system. The exercise session consisted of playing two rounds each of the game segments 20,000 Leaks, Reflex Ridge, and River Rush, each lasting approximately 3 minutes
Study NCT06728306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jacobson's Relaxation
Description: Participants underwent 20 minutes of progressive relaxation training as developed by Dr. Jacobson. The training involves a series of deep diaphragmatic breaths followed by the systematic tensing and relaxing of 16 major muscle groups throughout the body. Participants were guided through the exercise by an approximately 20-minute audio recording prepared by a psychologist and available online
Study NCT06007222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin group
Description: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
Study NCT06007222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-antithrombotic group
Description: No antithrombotic agents will be administered after randomization until the end of the study period.
Study NCT05243563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MonaLisa Touch
Description: 3 laser treatments at 6 week intervals for 6 months by a single trained operator
Study NCT05243563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical steroid
Description: self-applied topical steroid therapy using clobetasol propionate 0.05%
Study NCT05243563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical steroid
Description: self-applied topical steroid therapy using clobetasol propionate 0.05%
Study NCT04811014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine, Naloxone Drug Combination
Description: 8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
Study NCT04811014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Counseling
Description: One-on-one counseling with a licensed chemical dependency counselor
Study NCT04811014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support Services
Description: 24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management
Study NCT04811014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group
Description: Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups
Study NCT04811014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Medication Management
Description: Study staff will refer patients to long-term MOUD providers in the community
Study NCT04811014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive Outreach
Description: The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 1000 mg
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05343663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Self-Management Program Conducted with Tele-Nursing will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.